# PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

> **NCT01374789** · PHASE2 · TERMINATED · sponsor: **WiSP Wissenschaftlicher Service Pharma GmbH** · enrollment: 2 (actual)

## Conditions studied

- Urinary Bladder Cancer

## Interventions

- **DRUG:** GemCis + Panitumumab
- **DRUG:** GemCis

## Key facts

- **NCT ID:** NCT01374789
- **Lead sponsor:** WiSP Wissenschaftlicher Service Pharma GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated due to insufficient recruitment.
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374789, "PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01374789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*